Corona Remedies shares fell over 3% despite strong Q4FY26 and FY26 revenue and profit growth, margin pressure, acquisitions, capacity expansion and EAEU-GMP certification.
Corona Remedies shares fell over 3% despite strong Q4FY26 and FY26 revenue and profit growth, margin pressure, acquisitions, capacity expansion and EAEU-GMP certification.